The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin

被引:21
|
作者
Yamaguchi, Tetsuo [1 ]
Konishi, Hiroe [1 ,2 ]
Aoki, Kotaro [1 ]
Ishii, Yoshikazu [1 ]
Chono, Koji [3 ]
Tateda, Kazuhiro [1 ]
机构
[1] Toho Univ, Sch Med, Dept Microbiol & Infect Dis, Tokyo, Japan
[2] Toho Univ, Grad Sch Med, Div Pediat, Tokyo, Japan
[3] Astellas Pharma Inc, Res Portfolio Planning Drug Discovery & Res, Tsukuba, Ibaraki, Japan
关键词
16S rRNA; Clostridioides difficile; Fidaxomicin; Microbiota; RIBOTYPE; 027; MOUSE MODEL; INFECTION; LACTOFERRIN; STRAIN; SUSCEPTIBILITY; EPIDEMIOLOGY; RECURRENCE; PREVENTION; OUTCOMES;
D O I
10.1016/j.jiac.2019.12.020
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To investigate the effect of vancomycin and fidaxomicin on the diversity of intestinal microbiota in a mouse model of Clostridioides difficile infection. Methods: Mice were divided into 11 models (4 mice per model): 6 uninoculated models and 5 models inoculated with C. difficile BI/NAP1/027. Inoculated models were prepared using intraperitoneal clindamycin followed by inoculation with C. difficile BI/NAP1/027. Uninoculated and C. difficile-inoculated mice received 2 or 7 days' vancomycin or fidaxomicin. Clostridium butyricum MIYAIRI 588 probiotic and lactoferrin prebiotic were administered for 10 days to uninoculated mice. Intestinal microbiome composition was investigated by sequence analyses of bacterial 16S rRNA genes from faeces, and microbiota diversity estimated. Results: In uninoculated, untreated ('normal') mice, Clostridia (57.8%) and Bacteroidia (32.4%) accounted for the largest proportions of gut microbiota. The proportion of Clostridia was numerically reduced in C. difficile-inoculated versus normal mice. Administration of vancomycin to C. difficile-inoculated mice reduced the proportions of Bacteroidia and Clostridia, and increased that of Proteobacteria. Administration of fidaxomicin to C. difficile-inoculated mice reduced the proportion of Clostridia to a lesser extent, but increased that of Bacteroidia. Microbiota diversity was lower in C. difficile-inoculated versus normal mice (164.5 versus 349.1 operational taxonomic units (OTUs), respectively); treatment of C. difficile-inoculated mice with 7 days' vancomycin reduced diversity to a greater extent than did 7 days' fidaxomicin treatment (26.2 versus 134.2 OTUs, respectively). Conclusions: Both C. difficile inoculation and treatment with vancomycin or fidaxomicin reduced microbiota diversity; however, dysbiosis associated with fidaxomicin was milder than with vancomycin. (c) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:483 / 491
页数:9
相关论文
共 49 条
  • [31] Akkermansia muciniphila Ameliorates Clostridioides difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites
    Wu, Zhengjie
    Xu, Qiaomai
    Gu, Silan
    Chen, Yunbo
    Lv, Longxian
    Zheng, Beiwen
    Wang, Qiangqiang
    Wang, Kaicen
    Wang, Shuting
    Xia, Jiafeng
    Yang, Liya
    Bian, Xiaoyuan
    Jiang, Xianwan
    Zheng, Lisi
    Li, Lanjuan
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [32] Modulation of Lactobacillus rhamnosus GG on the gut microbiota and metabolism in mice with Clostridioides difficile infection
    Wu, Zhengjie
    Xu, Qiaomai
    Gu, Silan
    Wang, Qiangqiang
    Chen, Yunbo
    Lv, Longxian
    Zheng, Beiwen
    Wang, Kaicen
    Wang, Shuting
    Xia, Jiafeng
    Li, Lanjuan
    FOOD & FUNCTION, 2022, 13 (10) : 5667 - 5679
  • [33] Clostridioides difficile Colonization Is Differentially Associated With Gut Microbiome Profiles by Infant Feeding Modality at 3-4 Months of Age
    Drall, Kelsea M.
    Tun, Hein M.
    Morales-Lizcano, Nadia P.
    Konya, Theodore B.
    Guttman, David S.
    Field, Catherine J.
    Mandal, Rupasri
    Wishart, David S.
    Becker, Allan B.
    Azad, Meghan B.
    Lefebvre, Diana L.
    Mandhane, Plush J.
    Moraes, Theo J.
    Sears, Malcolm R.
    Turvey, Stuart E.
    Subbarao, Padmaja
    Scott, James A.
    Kozyrskyj, Anita L.
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [34] Which trials do we need? Fidaxomicin plus either intravenous metronidazole or tigecycline versus vancomycin plus either intravenous metronidazole or tigecycline for fulminant Clostridioides difficile infection
    Pipitone, Giuseppe
    Iaria, Chiara
    Granata, Guido
    Cascio, Antonio
    Maraolo, Alberto Enrico
    CLINICAL MICROBIOLOGY AND INFECTION, 2025, 31 (03) : 315 - 318
  • [35] The impact of ibezapolstat and other Clostridioides difficile infection-relevant antibiotics on the microbiome of humanized mice
    Wolfe, Trenton M.
    Jo, Jinhee
    Pinkham, Nick V.
    Garey, Kevin W.
    Walk, Seth T.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (04)
  • [36] Characterization of the gut microbiome of patients with Clostridioides difficile infection, patients with non-C. difficile diarrhea, and C. difficile-colonized patients
    Vazquez-Cuesta, Silvia
    Villar, Laura
    Lozano Garcia, Nuria
    Fernandez, Ana I.
    Olmedo, Maria
    Alcala, Luis
    Marin, Mercedes
    Munoz, Patricia
    Bouza, Emilio
    Reigadas, Elena
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
  • [37] Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure
    Chilton, C. H.
    Crowther, G. S.
    Freeman, J.
    Todhunter, S. L.
    Nicholson, S.
    Longshaw, C. M.
    Wilcox, M. H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (02) : 451 - 462
  • [38] Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin
    Merchante, Nicolas
    Herrero, Rocio
    Valverde-Fredet, Maria Dolores
    Rodriguez-Fernandez, Miguel
    Pinagorte, Hector
    Martinez-Marcos, Francisco J.
    Gil-Anguita, Concepcion
    Garcia-Lopez, Maria
    Pitarch, Maria Tasias
    De Medrano, Vicente Abril Lopez
    Lorite, Miguel Nicolas Navarrete
    Gomez-Ayerbe, Cristina
    Leon, Eva
    Gonazlez-De La Aleja, Pilar
    Castillo, Ana Ruiz
    Aller, Ana, I
    Rodriguez, Juan Carlos
    Fonseca, Julia Ternero
    Corzo, Juan E.
    Perez, Alberto Naranjo
    Trigo-Rodriguez, Marta
    Merino, Esperanza
    JAC-ANTIMICROBIAL RESISTANCE, 2023, 5 (02):
  • [39] Follow your Gut: Microbiome-Based Approaches in the Developmental Pipeline for the Prevention and Adjunctive Treatment of Clostridioides difficile Infection (CDI)
    A. J. Gonzales-Luna
    T. J. Carlson
    Current Infectious Disease Reports, 2020, 22
  • [40] Non-invasive treatment of Clostridioides difficile infection with a human-origin probiotic cocktail through gut microbiome-gut metabolome modulations
    Gurung, Bijay
    Courreges, Maria C.
    Pollak, Julie
    Malgor, Ramiro
    Jiang, Lin
    Wang, Bo
    Wang, Shaohua
    FRONTIERS IN MICROBIOLOGY, 2025, 16